Coverart for item
The Resource Anticoagulation therapy, Joe F. Lau, Geoffrey D. Barnes, Michael B. Streiff editors

Anticoagulation therapy, Joe F. Lau, Geoffrey D. Barnes, Michael B. Streiff editors

Label
Anticoagulation therapy
Title
Anticoagulation therapy
Statement of responsibility
Joe F. Lau, Geoffrey D. Barnes, Michael B. Streiff editors
Contributor
Editor
Subject
Language
eng
Summary
This book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. The field of anticoagulation therapy is evolving rapidly, particularly since the arrival and widespread adoption of direct oral anticoagulants. Organized in two parts, this book reviews the pharmacologic properties of various anticoagulants and details the clinical applications of anticoagulant therapy. Drugs such as warfarin and unfractionated heparin, as well as parenteral and direct oral anticoagulants are discussed in terms of their pharmacokinetics, drug-disease interactions, dosing strategies, and risk considerations. Clinical applications of anticoagulant therapy in disorders such as acute coronary syndromes, atrial fibrillation, and thrombophilia and in special populations such as pregnant women, the elderly, and in the patient with cancer are highlighted. Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, Anticoagulation Therapy is an essential resource for cardiologists, vascular medicine specialists, hematologists, internists, and all other healthcare professionals who prescribe anticoagulants
Member of
Cataloging source
N$T
Dewey number
615.718
Index
index present
LC call number
RM340
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Lau, Joe F.
  • Barnes, Geoffrey D.
  • Streiff, Michael B.
http://library.link/vocab/subjectName
  • Anticoagulants (Medicine)
  • Anticoagulants (Medicine)
  • Medicine & Public Health
  • Cardiology
  • Hematology
  • Angiology
Label
Anticoagulation therapy, Joe F. Lau, Geoffrey D. Barnes, Michael B. Streiff editors
Instantiates
Publication
Copyright
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Intro; Preface; Acknowledgments; Abbreviations; Contents; 1: Introduction; Anticoagulation Therapy: A Historical Perspective; The Evolving Anticoagulant Armamentarium; Resources for Anticoagulation Management; Exploring the Future of Anticoagulation Care; References; Part I: Anticoagulants; 2: Warfarin; Introduction; Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Pharmacodynamics; Clinical Utility; Practical Management; Patient Engagement and Education; Dosing: Initiation; Dosing: Maintenance; Administration; Monitoring
  • Transitioning Between Warfarin and Other AnticoagulantsManagement of Warfarin Around Elective Procedures; Adverse Effects; Skin Necrosis; Purple Toe Syndrome; Other Adverse Effects; Bleeding; Reversal; INR Derangements in Asymptomatic Patients; INR 9; Bleeding Events; Nonmajor Bleeding; Major Bleeding; Urgent or Emergent Procedures; Special Considerations; Pregnancy; Breastfeeding; Pediatric Patients; Conclusion; References; 3: Unfractionated Heparin and Low-­Molecular-­Weight Heparin; Introduction; Unfractionated Heparin; Pharmacokinetics and Pharmacodynamics
  • Clinical Indications and DosingMonitoring; Considerations in Special Populations; Obesity; Pregnancy; Strategies for Reversal of Unfractionated Heparin; Complications; Heparin Resistance; Osteopenia; Heparin-Induced Thrombocytopenia; Low-Molecular-Weight Heparin; Pharmacodynamics; Pharmacokinetics; Clinical Indications and Dosing; Considerations in Special Populations; Obesity; Renal Dysfunction and Elderly Patients; Pregnancy; Strategies for Reversal of Low-­Molecular-­Weight Heparins; Summary; References; 4: Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharides
  • Parenteral Direct Thrombin Inhibitors (Argatroban and Bivalirudin)Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Pharmacodynamics; Clinical Utility; Heparin-Induced Thrombocytopenia (HIT); Argatroban; Bivalirudin; Coronary Reperfusion; Percutaneous Coronary Intervention (PCI) in Patients without HIT; Argatroban; Bivalirudin; Percutaneous Coronary Intervention (PCI) in Patients with HIT; Argatroban; Bivalirudin; Acute Myocardial Infarction (NSTEMI or STEMI) in Patients Who Cannot Undergo PCI; CABG with or Without HIT
  • Practical ManagementDosing; Administration; Monitoring and Titration; HIT; Coronary Reperfusion; Argatroban; Bivalirudin; Transitioning to Oral Anticoagulation; HIT; Argatroban; Bivalirudin; Coronary Reperfusion; Other Clinical Uses; Continuous Renal Replacement Therapy; ECMO; Adverse Effects; Reversal; Special Considerations; Pregnancy; Breastfeeding; Pediatric; Fondaparinux; Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Renal Function; Age; Low Body Weight; Pharmacodynamics; Clinical Utility; Prevention of VTE; Orthopedic Surgery
Extent
1 online resource.
Form of item
online
Isbn
9783319737096
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-3-319-73709-6
System control number
  • on1031847557
  • (OCoLC)1031847557
Label
Anticoagulation therapy, Joe F. Lau, Geoffrey D. Barnes, Michael B. Streiff editors
Publication
Copyright
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
cr
Carrier MARC source
rdacarrier
Content category
text
Content type code
txt
Content type MARC source
rdacontent
Contents
  • Intro; Preface; Acknowledgments; Abbreviations; Contents; 1: Introduction; Anticoagulation Therapy: A Historical Perspective; The Evolving Anticoagulant Armamentarium; Resources for Anticoagulation Management; Exploring the Future of Anticoagulation Care; References; Part I: Anticoagulants; 2: Warfarin; Introduction; Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Pharmacodynamics; Clinical Utility; Practical Management; Patient Engagement and Education; Dosing: Initiation; Dosing: Maintenance; Administration; Monitoring
  • Transitioning Between Warfarin and Other AnticoagulantsManagement of Warfarin Around Elective Procedures; Adverse Effects; Skin Necrosis; Purple Toe Syndrome; Other Adverse Effects; Bleeding; Reversal; INR Derangements in Asymptomatic Patients; INR 9; Bleeding Events; Nonmajor Bleeding; Major Bleeding; Urgent or Emergent Procedures; Special Considerations; Pregnancy; Breastfeeding; Pediatric Patients; Conclusion; References; 3: Unfractionated Heparin and Low-­Molecular-­Weight Heparin; Introduction; Unfractionated Heparin; Pharmacokinetics and Pharmacodynamics
  • Clinical Indications and DosingMonitoring; Considerations in Special Populations; Obesity; Pregnancy; Strategies for Reversal of Unfractionated Heparin; Complications; Heparin Resistance; Osteopenia; Heparin-Induced Thrombocytopenia; Low-Molecular-Weight Heparin; Pharmacodynamics; Pharmacokinetics; Clinical Indications and Dosing; Considerations in Special Populations; Obesity; Renal Dysfunction and Elderly Patients; Pregnancy; Strategies for Reversal of Low-­Molecular-­Weight Heparins; Summary; References; 4: Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharides
  • Parenteral Direct Thrombin Inhibitors (Argatroban and Bivalirudin)Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Pharmacodynamics; Clinical Utility; Heparin-Induced Thrombocytopenia (HIT); Argatroban; Bivalirudin; Coronary Reperfusion; Percutaneous Coronary Intervention (PCI) in Patients without HIT; Argatroban; Bivalirudin; Percutaneous Coronary Intervention (PCI) in Patients with HIT; Argatroban; Bivalirudin; Acute Myocardial Infarction (NSTEMI or STEMI) in Patients Who Cannot Undergo PCI; CABG with or Without HIT
  • Practical ManagementDosing; Administration; Monitoring and Titration; HIT; Coronary Reperfusion; Argatroban; Bivalirudin; Transitioning to Oral Anticoagulation; HIT; Argatroban; Bivalirudin; Coronary Reperfusion; Other Clinical Uses; Continuous Renal Replacement Therapy; ECMO; Adverse Effects; Reversal; Special Considerations; Pregnancy; Breastfeeding; Pediatric; Fondaparinux; Pharmacology; Mechanism of Action; Pharmacokinetics; Absorption; Distribution; Metabolism; Elimination; Renal Function; Age; Low Body Weight; Pharmacodynamics; Clinical Utility; Prevention of VTE; Orthopedic Surgery
Extent
1 online resource.
Form of item
online
Isbn
9783319737096
Media category
computer
Media MARC source
rdamedia
Media type code
c
Other control number
10.1007/978-3-319-73709-6
System control number
  • on1031847557
  • (OCoLC)1031847557

Library Locations

Processing Feedback ...